151 related articles for article (PubMed ID: 38175344)
41. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
42. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
[TBL] [Abstract][Full Text] [Related]
43. Optimizing adjuvant and post-neoadjuvant therapy in HER2-positive early breast cancer.
Barot SV; Roesch E; Abraham J
Expert Rev Anticancer Ther; 2022 Dec; 22(12):1289-1299. PubMed ID: 36373394
[TBL] [Abstract][Full Text] [Related]
44. Genomic Impact of Neoadjuvant Therapy on Breast Cancer: Incomplete Response is Associated with Altered Diagnostic Gene Signatures.
Beitsch P; Whitworth P; Baron P; Pellicane J; Treece T; Yoder E; Gittleman M;
Ann Surg Oncol; 2016 Oct; 23(10):3317-23. PubMed ID: 27384749
[TBL] [Abstract][Full Text] [Related]
45. Treatment Strategies for Residual Disease following Neoadjuvant Chemotherapy in Patients with Early-Stage Breast Cancer.
Abdel-Razeq H; Khalil H; Assi HI; Dargham TB
Curr Oncol; 2022 Aug; 29(8):5810-5822. PubMed ID: 36005196
[TBL] [Abstract][Full Text] [Related]
46. Potential value of tumor stiffness and sE-cadherin in predicting the response to neoadjuvant therapy in HER2-positive breast cancers.
Zhou W; Wu M; Lin H; Chen W; Lu G; Yang F; Chen Y; Chen G
Future Oncol; 2022 Aug; 18(25):2817-2825. PubMed ID: 35730465
[TBL] [Abstract][Full Text] [Related]
47. Is there still a role for neoadjuvant therapy in breast cancer?
Shannon C; Smith I
Crit Rev Oncol Hematol; 2003 Jan; 45(1):77-90. PubMed ID: 12482573
[TBL] [Abstract][Full Text] [Related]
48. Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges.
Heil J; Kuerer HM; Pfob A; Rauch G; Sinn HP; Golatta M; Liefers GJ; Vrancken Peeters MJ
Ann Oncol; 2020 Jan; 31(1):61-71. PubMed ID: 31912797
[TBL] [Abstract][Full Text] [Related]
49. Timing to imaging and surgery after neoadjuvant therapy for breast cancer.
Grubstein A; Rapson Y; Stemmer SM; Allweis T; Wolff-Bar M; Borshtein S; Eden S; Tamir S; Atar E; Sharon E; Shochat T; Yerushalmi R
Clin Imaging; 2021 Mar; 71():24-28. PubMed ID: 33171362
[TBL] [Abstract][Full Text] [Related]
50. Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Halim A; Wahba H
Med Oncol; 2012 Jun; 29(2):454-8. PubMed ID: 21350875
[TBL] [Abstract][Full Text] [Related]
51. Treatment outcome in patients with breast conserving surgery after neoadjuvant therapy for breast carcinoma - a single institution experience.
Martinovic A; Santrac N; Bozovic-Spasojevic I; Nikolic S; Markovic I; Lukic B; Gavrilovic D; Granic M; Dzodic R
J BUON; 2018; 23(4):883-890. PubMed ID: 30358190
[TBL] [Abstract][Full Text] [Related]
52. Dynamic contrast-enhanced MR imaging in a phase Ⅱ study on neoadjuvant chemotherapy combining Rh-endostatin with docetaxel and epirubicin for locally advanced breast cancer.
Jia Q; Xu J; Jiang W; Zheng M; Wei M; Chen J; Wang L; Huan Y
Int J Med Sci; 2013; 10(2):110-8. PubMed ID: 23329881
[TBL] [Abstract][Full Text] [Related]
53. Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer.
Schmidt H; Zhaveri S; Valente C; Pisapati K; Pickholz E; Weltz S; Nayak A; Oza T; Corben A; Weltz C; Port E; Jaffer S
Breast J; 2021 Feb; 27(2):120-125. PubMed ID: 33393166
[TBL] [Abstract][Full Text] [Related]
54. Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years.
Dredze LM; Friger M; Ariad S; Koretz M; Delgado B; Shaco-Levy R; Tokar M; Bayme M; Agassi R; Rosenthal M; Dyomin V; Belochitski O; Libson S; Mizrahi T; Geffen DB
Breast Cancer Res Treat; 2022 Jun; 193(3):597-612. PubMed ID: 35451732
[TBL] [Abstract][Full Text] [Related]
55. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.
Marra A; Curigliano G
Cancer J; 2021 Jan-Feb 01; 27(1):41-49. PubMed ID: 33475292
[TBL] [Abstract][Full Text] [Related]
57. [Axillary pathologic response after neoadjuvant chemotherapy in locally advanced breast cancer with axillary involvement].
Jiménez-Ballvé A; Serrano-Palacio A; García-Sáenz JA; Ortega Candil A; Salsidua-Arroyo O; Román-Santamaría JM; Pelayo Alarcón A; Fuentes Ferrer ME; Carreras-Delgado JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(4):230-5. PubMed ID: 25743035
[TBL] [Abstract][Full Text] [Related]
58. Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A; Gil M; Sánchez-Rovira P; Llombart A; Adrover E; Estevez LG; de la Haba J; Calvo L
Anticancer Drugs; 2008 Apr; 19(4):339-47. PubMed ID: 18454044
[TBL] [Abstract][Full Text] [Related]
59. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
[TBL] [Abstract][Full Text] [Related]
60. Progress in evaluation of pathologic response to neoadjuvant chemotherapy of breast cancer.
Gebreamlak EP; Tse GM; Niu Y
Anticancer Agents Med Chem; 2013 Feb; 13(2):222-6. PubMed ID: 22934701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
